SHIFT Newsroom · UK

Rybelsus (semaglutide tablets) formulation change poses medication error risk

The MHRA has issued a drug safety update regarding the transition to a new formulation of Rybelsus (semaglutide tablets), highlighting the risk of medication errors.

By SHIFT AI Newsroom · Published 10 September 2026

How we prepare and check newsroom articles · Report a correction

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update regarding the transition to a new formulation of Rybelsus (semaglutide tablets). The update highlights the risk of medication errors if healthcare professionals are not aware of the change.

SHIFT’s take

What we think this could mean for you, and what remains uncertain.

This change affects patients in the UK who are taking Rybelsus (semaglutide tablets) for their condition, and healthcare professionals must be aware of the new formulation to prevent medication errors.

Known facts

The MHRA has issued a drug safety update on the transition to a new formulation of Rybelsus (semaglutide tablets).

Sources and evidence

MHRA — Source date: 17 December 2025

← Back to SHIFT Newsroom